Day: December 8, 2019

– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients –– Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase Deficiency –– Additional Data for the Phase 2 Study of Mitapivat in Thalassemia to be Presented at a Medical Meeting in the First Half of 2020 –– Company to Host ASH Investor Event and Webcast Monday, December 9 at 8:00 p.m. ET –CAMBRIDGE, Mass., Dec. 08, 2019 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that clinical proof-of-concept has been established based on a preliminary analysis of the Phase 2 trial of mitapivat (AG-348) in patients with non-transfusion-dependent thalassemia. Mitapivat is an investigational,...

— Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma —— All Oral Regimen of Once-Weekly Selinexor with Revlimid® and Low Dose Dexamethasone Achieves High Response Rates in Patients with Newly Diagnosed Multiple Myeloma —— STORM Study Patients Treated with Selinexor Achieved Survival Advantage Over Matched Patients from the MAMMOTH Study Who Were Treated with Other Anti-Myeloma Agents —— Single-Agent Oral Eltanexor Shows Encouraging Activity in Elderly Patients with Higher-Risk Myelodysplastic Syndrome —NEWTON, Mass., Dec. 08, 2019 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI),...

                Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up dataInnate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) shared new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox-tdfk) today at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, USA, which expands on the efficacy results and affirms the manageable safety profile of the medicine. The final analysis showed that 36 percent (29/80) of the relapsed or refractory hairy cell leukemia patients achieved durable complete response (CR) with Lumoxiti at Day 181 of patients’ respective evaluation, compared to the primary analysis in which 30...

L’analyse finale s’appuie sur les résultats de l’étude pivot de Phase III de Lumoxiti dans la leucémie à tricholeucocytes ; des réponses complètes et durables sont maintenues dans les données de suivi de long terme.Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a aujourd’hui partagé de nouvelles données de long terme issues de l’essai pivot de Phase III évaluant Lumoxiti (moxetumomab pasudotox-tdfk) au 61ème congrès annuel de la Société Américaine d’Hématologie ( « ASH » ) à Orlando aux Etats-Unis. Ces données renforcent les résultats d’efficacité et confirment le profil de tolérance du médicament. L’analyse finale montre que 36% (29/80) des patients présentant une leucémie à tricholeucocytes en rechute ou réfractaire ont eu une réponse complète durable avec...

Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T90% complete response and 100% overall survival at 12 months in CAR T naive pediatric ALL patients dosed with AUTO3Investor call to be held December 9 at 8:30 am ET / 1:30 pm GMT to review dataLONDON, Dec. 08, 2019 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL) announced today new data highlighting progress on AUTO3, the first-in-human bicistronic CD19 and CD22 CAR, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and pediatric acute lymphoblastic leukemia (ALL). The data were presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL.“DLBCL is an aggressive and rapidly progressing cancer, and early response is critical to ensuring positive outcomes...

Company Announcement 8 December 2019Nasdaq has announced today that Coop Pank AS shares (trading ticker: CPA1T) will be listed on the Baltic Main List on Tuesday, December 10, 2019.Further information: https://cns.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=914356&messageId=1152002Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. It has 15 branch offices and 28 banking points all over the country. The number of clients using Coop Pank for their daily banking is 58,300. Coop Pank aims to put the synergy generated by the interaction of retail business and banking to good use and to bring everyday banking services closer to people’s homes. The main shareholder of the bank is the domestic retail chain Coop Eesti comprising 340 stores. Further information: Kristjan Seema Head...

Börsiteade 8. detsember 2019Nasdaq teatas täna, et Coop Pank AS-i aktsiad (kauplemistähis: CPA1T) noteeritakse Balti põhinimekirjas teisipäeval, 10. detsembril 2019.Täiendav informatsioon: https://cns.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=914356&messageId=1152001Eesti kapitalil põhinev Coop Pank on üks viiest Eestis tegutsevast universaalpangast. Coop Pangal on üle Eesti 15 pangakontorit ja 28 pangapunkti. Pangal on 58 300 igapäevapanganduse klienti. Coop Pank kasutab jaekaubanduse ja panganduse vahel tekkivat sünergiat ning toob igapäevased pangateenused inimeste kodu lähedale. Panga enamusaktsionäriks on kodumaine kaubanduskett Coop Eesti, mille müügivõrgustikku kuulub 340 kauplust.Lisainfo: Kristjan Seema Turundus- ja kommunikatsioonijuht +372 5505 253 kristjan.seema@cooppank.ee

In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemiaAt four-year follow-up of the MURANO study, Venclexta/Venclyxto plus MabThera/Rituxan continued to reduce disease progression compared to a standard-of-care therapy in previously treated chronic lymphocytic leukaemiaData presented on both studies include results on minimal residual disease, which is currently emerging as a potential surrogate endpoint             Basel, 8 December 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data from two pivotal phase III Venclexta®/Venclyxto® (venetoclax) studies (MURANO and CLL14) that highlight Venclexta/Venclyxto combination treatments as chemotherapy-free, fixed-duration options...

BOSTON and LONDON, Dec. 08, 2019 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, will be presenting new registrational data from multiple programs at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2019 in Orlando, FL.On Sunday, December 8, 2019, investigators will describe ongoing clinical progress for two lead development programs in the company’s primary immune deficiencies portfolio: OTL-103, an investigational gene therapy in development for the treatment of Wiskott-Aldrich syndrome (WAS) at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy; and OTL-101, an investigational...